Handok, Inc. stock analysis
Want to see KR:002390 full AI Analyst Report?
Handok, Inc. (002390) Stock Price & Analysis
002390 Stock Chart & Stats
- Day’s Range
- KRW 8,030.00 - KRW 8,300.00
- 52-Week Range
- KRW 6,460.00 - KRW 12,150.00
- Previous Close
- KRW 8,210.00
- Volume
- N/A
- Average Volume (3M)
- 4,727
- Market Cap
- KRW 113.00B
- Enterprise Value
- KRW 444.50B
- Total Cash (Recent Filing)
- KRW 25.80B
- Total Debt (Recent Filing)
- KRW 376.66B
- Price to Earnings (P/E)
- ―
- Beta
- -0.02
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Feb 26, 2026
- Dividend Yield
- 2.42%
Bulls Say, Bears Say
Bulls Say
TTM Revenue Rebound
The sharp TTM revenue rebound indicates a meaningful recovery in commercial activity after two years of declines. If maintained, stronger scale can support operating leverage, improve the absorption of fixed costs, and provide a broader base for restoring sustainable profitability.
Improved Operating Profitability
Returning to positive EBITDA and operating profitability shows that the business has improved substantially from its 2024 trough. This operational recovery is important because continued margin improvement could help convert renewed revenue into stronger earnings and reduce dependence on external funding.
Established Healthcare Commercialization Model
Handok operates across development, manufacturing, marketing, and commercialization of prescription and healthcare products, serving hospitals, clinics, and pharmacies. This established channel coverage provides a durable framework for distributing products and supporting recurring healthcare demand.
Bears Say
Persistent Net Losses
Despite the recovery in revenue and operating profit, Handok has not yet reached consistent bottom-line profitability. Ongoing net losses weaken retained equity, limit internally generated capital, and indicate that the current operating improvement has not fully translated into durable shareholder returns.
Negative Free Cash Flow
Negative free cash flow means the company is not currently generating enough cash after investment needs to fund its business internally. Continued cash conversion weakness can increase funding pressure, restrict strategic flexibility, and make the revenue recovery less valuable unless cash generation improves.
Higher Leverage And Weak Returns
Rising debt relative to equity has reduced financial flexibility while declining equity and negative ROE show that shareholder capital is not currently producing positive returns. This combination can constrain investment capacity and amplify the consequences if profitability recovery stalls.
002390 FAQ
What was Handok, Inc.’s price range in the past 12 months?
What is Handok, Inc.’s market cap?
When is Handok, Inc.’s upcoming earnings report date?
How were Handok, Inc.’s earnings last quarter?
Is Handok, Inc. overvalued?
Does Handok, Inc. pay dividends?
What is Handok, Inc.’s EPS estimate?
How many shares outstanding does Handok, Inc. have?
What happened to Handok, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Handok, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Handok, Inc.
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Cho Jae-cheon
- Employees
- 951
- Website
- www.handok.co.kr
- Address
- 132 Teheran-ro, Seoul, SL, 06235, KR
Handok, Inc. (002390) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |

